22nd Jan 2024 Zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment- a plain language summary
12th Apr 2023 Plain Language Summary : iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström’s macroglobulinemia